Literature DB >> 7942820

Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience.

L U Mailloux1, B Napolitano, A G Bellucci, M Vernace, B M Wilkes, R T Mossey.   

Abstract

In the United States, the incidence of end-stage renal disease to hypertension has increased sharply over the last 8 years, especially in elderly white dialysis patients who demonstrate very poor survival rates. The 5-year survival rates were near 20% for patients 65 to 74 years old and 9% for those > or = 75 years of age. Our program experienced a sharp increase in cases of end-stage renal disease due to renal vascular disease after 1982. Renal vascular disease was characterized clinically in 83 of 683 dialysis patients either by angiography or asymmetric kidney size in patients with evidence of systemic atherosclerosis, hypertension, insignificant proteinuria, and a benign urinary sediment. The median age was 70 years, with 84% of the patients being older than 61 years. These patients had 56% 2-year, 18% 5-year, and 5% 10-year survival rates, which are quite similar to the 1992 US Renal Data System data. Patients with renal vascular disease have a significantly worse prognosis than other diagnostic groups, most likely due to their older age, underlying vascular disease, and coronary artery disease. We feel that a significant number of elderly white hypertensive patients described in the 1992 US Renal Data Service report have renal vascular disease as a cause of end-stage renal disease, highlighting the need to establish correct renal diagnoses. Hypertension should not be the end-stage renal disease diagnosis in elderly white hypertensive patients if clinical criteria suggest a diagnosis of renal vascular disease.

Entities:  

Mesh:

Year:  1994        PMID: 7942820     DOI: 10.1016/s0272-6386(12)80223-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  33 in total

Review 1.  Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure.

Authors:  J E Scoble
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

Review 2.  Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention.

Authors:  R G Woolfson
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

3.  Renal Artery Stenosis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

4.  Embolic protection device use in renal artery stent placement.

Authors:  Mallik R Thatipelli; Sanjay Misra; Srinivas R Sanikommu; Robert M Schainfeld; Sandeep K Sharma; Peter A Soukas
Journal:  J Vasc Interv Radiol       Date:  2009-03-27       Impact factor: 3.464

5.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

6.  Hypertension and renal failure.

Authors:  D J Goldsmith; G Hamilton
Journal:  Postgrad Med J       Date:  1998-05       Impact factor: 2.401

7.  Effect of Huanshuai Recipe Oral Liquid ([characters: see text]) on renal dysfunction progression in patients with atherosclerotic renal artery stenosis.

Authors:  Xiu-juan Wang; Xiang-rong Rao; Shen Li; Li Wang; Chang Liu; Gai-hua Zhang; Dong-yan Han; Yu Zhao; Nan-nan Zhang; Xue-xia Li; Shuai Chen
Journal:  Chin J Integr Med       Date:  2015-04-06       Impact factor: 1.978

Review 8.  Diagnosis and management of atherosclerotic renal artery stenosis: improving patient selection and outcomes.

Authors:  Christopher J White; Jeffrey W Olin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

9.  Renal Failure Patients in Disasters.

Authors:  Kenneth D Lempert; Jeffrey B Kopp
Journal:  Disaster Med Public Health Prep       Date:  2019-05-06       Impact factor: 1.385

10.  Is race a risk factor for the development of renal artery stenosis?

Authors:  Ayad Jazrawi; Saba Darda; Peter Burke; Marcos Daccarett; Josef Stehlik; Shukri David; Marcel Zughaib
Journal:  Cardiol Res Pract       Date:  2009-11-17       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.